The Company’s Board of Directors agreed to the delisting of all the shares from the Alternative Stock Market
On November 22nd, the Company’s Board of Directors agreed to the delisting of all the shares representing the capital stock of AB-BIOTICS, SA from the Alternative Stock Market, as well as the delegation of powers in favour of the Executive Directors to the aforementioned effects, so that they may act on behalf...
Kaneka takes over 86.6% of AB-Biotics’ share capital
AB-Biotics has announced, as a relevant fact, that the offer to acquire shares of Kaneka, in the context of the delisting of the Spanish company, has been accepted by 2,292. 426 shares, an amount that represents 57.62% of the shares to the offerees and 18.21% of the company's share capital. In addition,...
AB-Biotics launches a psychobiotic that reduces stress and anxiety
AB-Biotics and Kaneka Probiotics were active participants at the Probiota Asia congress held in Singapore between October 22nd and 24th, organized by NutraIngredients-Asia. This annual event focuses on the pharmaceutical and food industry market for probiotics, prebiotics and microbiota. AB-Biotics, together with its main shareholder, Kaneka Probiotics, played a leading role, thanks...
AB-Biotics & Kaneka Probiotics visited Probiota Asia in Singapore
This event took place in Singapore, on October between 22th and 24th. This is a forum focused in prebiotic, probiotic and microbiota which scientists and delegates from food and pharma industries are the main visitors, to uncover business opportunities, stimulate innovation and drive collaboration. AB-Biotics & Kaneka Probiotics had a leading role...
Eighty-two percent of the shareholders from AB-Biotics approve of the exclusion of the company from the Alternative Stock Market
AB-Biotics celebrates at the Stock market of Barcelona an Extraordinary Shareholders Meeting which approved the proposal to exclude from the negotiation all of the company’s shares in the Alternative Stock Market. The Board counted with an assistance of shareholders who possess 96.5% of the social capital of the company. The 82.06% voted...
AB-Biotics presents biannual benefits for the first time
AB-Biotics has published the biannual accounts for the fiscal year 2019 where it has presented a positive result of 772,000 euros, against a loss of 377,000 from the first semester of last year, which means that this is the first semester that ever presents profits in its history. Furthermore, during the first...
AB-Biotics visited Vitafoods Asia
AB-Biotics has visited Vitafoods Asia, an event that was hold on September 25th and 26th in Singapore. Vitafoods Asia shapes the food industry for optimal health through science and innovation. Asia’s No.1 nutraceutical event connects over 350 international suppliers and 6,000+ business leaders who are looking to source the most innovative and...
AB-Biotics proves the efficiency of the use of pharmacogenetics as a treatment of depression
AB-Biotics just published in the journal Pharmaceutics the results from a meta-analysis that prove the clinical utility of Neurofarmagen®, a pharmacogenetics tool, to select and guide the prescription of psychiatric drugs in adult patients with major depression, especially moderate-severe. For the development of this study, three clinical studies that were carried out...
The Board of Directors calls for an Extraordinary Shareholders Meeting to be held on October 4th
The Board of Directors of AB-Biotics calls for an Extraordinary Shareholders Meeting to be held on October 4th at the Barcelona Stock Exchange to approve the proposal to delist all the company’s shares from the Alternative Stock Market (MAB). In the event that the proposal is approved, Kaneka will leave an opening...